XRCC5 and melanoma: It is intriguing to test if HNI-38 can also inhibit the Ku80-regulated PDK1 expression, and synergize the oncostatic effect of melatonin, indicating that melatonin and Ku80 inhibitors in combination might be useful for melanoma treatment.